Crunch!, page-4

BT,
I do hear what you say, but in relation to the value of PrIME for NSP shareholders, I think it is reassuring to note that Alison Coutts is also on the Board of PrIME as an independent director.
Likewise the percentage of shares controlled by the former directors of NSP, including those who are now directors of PrIME should ensure an alignment of interests for them to want to grow and deliver value to all shareholders. It is interesting that the recent financials demonstrate 92.737% of the equity is held by just 172 shareholders who control 158,820,985 of the 171,259,376 shares on issue. Even more interesting is the top 20 shareholders on page 64.....lots of familiar names there controlling 64.143%!
My hope (and expectation) is that the entrepreneurs, who have fought tooth and nail over the years to achieve a commercial product outcome, will stand to benefit handsomely (along with the PrIME partners) in any future buyout by one of the large blood/plasma companies. This is simply because of the large shareholdings (read skin in the game) of those key people, which I think aligns their interests with us ordinary shareholders.
BT, this is part of what encourages me to have patience....though I will always readily acknowledge that my investment in NSP is still a speculative play.
I note the SP is headed back north today.
Kind regards,